Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Rating of “Moderate Buy” from Analysts

Zura Bio Limited (NASDAQ:ZURA) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $10.75.

Several research firms recently commented on ZURA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research note on Wednesday, April 8th. Oppenheimer lowered their price target on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Friday, March 20th. Finally, Chardan Capital boosted their price target on shares of Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, March 23rd.

Zura Bio Price Performance

NASDAQ:ZURA opened at $5.35 on Friday. The stock has a market cap of $507.61 million, a P/E ratio of -4.91 and a beta of 0.03. Zura Bio has a one year low of $1.00 and a one year high of $7.44. The company has a fifty day moving average price of $4.47 and a 200 day moving average price of $5.25.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, equities research analysts anticipate that Zura Bio will post -0.76 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of the business. Suvretta Capital Management LLC increased its holdings in Zura Bio by 1.7% in the 4th quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock valued at $29,171,000 after buying an additional 94,110 shares during the period. VR Adviser LLC increased its holdings in Zura Bio by 15.4% in the 4th quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock valued at $28,008,000 after buying an additional 713,899 shares during the period. JPMorgan Chase & Co. increased its holdings in Zura Bio by 78.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after buying an additional 2,052,732 shares during the period. Siren L.L.C. increased its holdings in Zura Bio by 187.3% in the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock valued at $22,222,000 after buying an additional 2,434,866 shares during the period. Finally, Commodore Capital LP bought a new stake in Zura Bio in the 1st quarter valued at $19,338,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.